Systemic CD4 immunity and PD-L1/PD-1 blockade immunotherapy

PD-L1/PD-1 blockade immunotherapy has changed the therapeutic approaches for the treatment of many cancers. Nevertheless, the mechanisms underlying its efficacy or treatment failure are still unclear. Proficient systemic immunity seems to be a prerequisite for efficacy, as recently shown in patients...

Descripción completa

Detalles Bibliográficos
Autores: Escors Murugarren, David, Bocanegra Gondán, Ana Isabel, Chocarro de Erauso, Luisa, Blanco, Ester, Piñeiro Hermida, Sergio, Garnica, Maider, Fernández Rubio, Leticia, Vera García, Ruth, Arasanz Esteban, Hugo, Kochan, Grazyna
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Universidad Pública de Navarra
Repositorio:Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
OAI Identifier:oai:academica-e.unavarra.es:2454/45140
Acceso en línea:https://hdl.handle.net/2454/45140
Access Level:acceso abierto
Palabra clave:Biomarker
Immune checkpoint
T lymphocytes
id ES_cccc2c8fff37cbd9eef20dd84fed30b1
oai_identifier_str oai:academica-e.unavarra.es:2454/45140
network_acronym_str ES
network_name_str España
repository_id_str
spelling Systemic CD4 immunity and PD-L1/PD-1 blockade immunotherapyEscors Murugarren, DavidBocanegra Gondán, Ana IsabelChocarro de Erauso, LuisaBlanco, EsterPiñeiro Hermida, SergioGarnica, MaiderFernández Rubio, LeticiaVera García, RuthArasanz Esteban, HugoKochan, GrazynaBiomarkerImmune checkpointT lymphocytesPD-L1/PD-1 blockade immunotherapy has changed the therapeutic approaches for the treatment of many cancers. Nevertheless, the mechanisms underlying its efficacy or treatment failure are still unclear. Proficient systemic immunity seems to be a prerequisite for efficacy, as recently shown in patients and in mouse models. It is widely accepted that expansion of anti-tumor CD8 T cell populations is principally responsible for anti-tumor responses. In contrast, the role of CD4 T cells has been less studied. Here we review and discuss the evidence supporting the contribution of CD4 T cells to anti-tumor immunity, especially recent advances linking CD4 T cell subsets to efficacious PD-L1/PD-1 blockade immunotherapy. We also discuss the role of CD4 T cell memory subsets present in peripheral blood before the start of immunotherapies, and their utility as predictors of response.The OncoImmunology group is funded by the Spanish Association against Cancer (AECC, PROYE16001ESCO); Instituto de Salud Carlos III (ISCIII)-FEDER project grants (FIS PI17/02119, FIS PI20/00010, COV20/00000, and TRANSPOCART ICI19/00069); a Biomedicine Project grant from the Department of Health of the Government of Navarre (BMED 050-2019); Strategic projects from the Department of Industry, Government of Navarre (AGATA, Ref 0011-1411-2020-000013; LINTERNA, Ref. 0011-1411-2020-000033; DESCARTHES, 0011-1411-2019-000058); This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 848166.MDPICiencias de la SaludOsasun Zientziak2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2454/45140reponame:Academica-e. Repositorio Institucional de la Universidad Pública de Navarrainstname:Universidad Pública de NavarraInglésinfo:eu-repo/grantAgreement/European Commission/Horizon 2020 Framework Programme/848166info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI17%2F02119info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI20%2F00010info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/ICI19%2F00069info:eu-repo/grantAgreement/Gobierno de Navarra//BMED 050-2019info:eu-repo/grantAgreement/Gobierno de Navarra//AGATA, Ref 0011-1411-2020-000013info:eu-repo/grantAgreement/Gobierno de Navarra//LINTERNA, Ref. 0011-1411-2020-000033info:eu-repo/grantAgreement/Gobierno de Navarra//DESCARTHES, 0011-1411-2019-000058© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:academica-e.unavarra.es:2454/451402026-06-17T12:41:47Z
dc.title.none.fl_str_mv Systemic CD4 immunity and PD-L1/PD-1 blockade immunotherapy
title Systemic CD4 immunity and PD-L1/PD-1 blockade immunotherapy
spellingShingle Systemic CD4 immunity and PD-L1/PD-1 blockade immunotherapy
Escors Murugarren, David
Biomarker
Immune checkpoint
T lymphocytes
title_short Systemic CD4 immunity and PD-L1/PD-1 blockade immunotherapy
title_full Systemic CD4 immunity and PD-L1/PD-1 blockade immunotherapy
title_fullStr Systemic CD4 immunity and PD-L1/PD-1 blockade immunotherapy
title_full_unstemmed Systemic CD4 immunity and PD-L1/PD-1 blockade immunotherapy
title_sort Systemic CD4 immunity and PD-L1/PD-1 blockade immunotherapy
dc.creator.none.fl_str_mv Escors Murugarren, David
Bocanegra Gondán, Ana Isabel
Chocarro de Erauso, Luisa
Blanco, Ester
Piñeiro Hermida, Sergio
Garnica, Maider
Fernández Rubio, Leticia
Vera García, Ruth
Arasanz Esteban, Hugo
Kochan, Grazyna
author Escors Murugarren, David
author_facet Escors Murugarren, David
Bocanegra Gondán, Ana Isabel
Chocarro de Erauso, Luisa
Blanco, Ester
Piñeiro Hermida, Sergio
Garnica, Maider
Fernández Rubio, Leticia
Vera García, Ruth
Arasanz Esteban, Hugo
Kochan, Grazyna
author_role author
author2 Bocanegra Gondán, Ana Isabel
Chocarro de Erauso, Luisa
Blanco, Ester
Piñeiro Hermida, Sergio
Garnica, Maider
Fernández Rubio, Leticia
Vera García, Ruth
Arasanz Esteban, Hugo
Kochan, Grazyna
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Ciencias de la Salud
Osasun Zientziak
dc.subject.none.fl_str_mv Biomarker
Immune checkpoint
T lymphocytes
topic Biomarker
Immune checkpoint
T lymphocytes
description PD-L1/PD-1 blockade immunotherapy has changed the therapeutic approaches for the treatment of many cancers. Nevertheless, the mechanisms underlying its efficacy or treatment failure are still unclear. Proficient systemic immunity seems to be a prerequisite for efficacy, as recently shown in patients and in mouse models. It is widely accepted that expansion of anti-tumor CD8 T cell populations is principally responsible for anti-tumor responses. In contrast, the role of CD4 T cells has been less studied. Here we review and discuss the evidence supporting the contribution of CD4 T cells to anti-tumor immunity, especially recent advances linking CD4 T cell subsets to efficacious PD-L1/PD-1 blockade immunotherapy. We also discuss the role of CD4 T cell memory subsets present in peripheral blood before the start of immunotherapies, and their utility as predictors of response.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2454/45140
url https://hdl.handle.net/2454/45140
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv info:eu-repo/grantAgreement/European Commission/Horizon 2020 Framework Programme/848166
info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI17%2F02119
info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI20%2F00010
info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/ICI19%2F00069
info:eu-repo/grantAgreement/Gobierno de Navarra//BMED 050-2019
info:eu-repo/grantAgreement/Gobierno de Navarra//AGATA, Ref 0011-1411-2020-000013
info:eu-repo/grantAgreement/Gobierno de Navarra//LINTERNA, Ref. 0011-1411-2020-000033
info:eu-repo/grantAgreement/Gobierno de Navarra//DESCARTHES, 0011-1411-2019-000058
dc.rights.none.fl_str_mv https://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
instname:Universidad Pública de Navarra
instname_str Universidad Pública de Navarra
reponame_str Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
collection Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419752418443264
score 15,811543

Similares en LA Referencia